+关注
VictorChai
暂无个人介绍
IP属地:未知
8
关注
3
粉丝
0
主题
0
勋章
主贴
热门
VictorChai
2021-06-15
$Apple(AAPL)$
Long Apple
VictorChai
2021-06-15
Ok
抱歉,原内容已删除
VictorChai
2021-06-15
👍
抱歉,原内容已删除
VictorChai
2021-03-06
Price below $700 would be a good entry point
What's the Outlook for Intuitive Surgical?
VictorChai
2021-03-05
Time to shop on Taobao
抱歉,原内容已删除
VictorChai
2021-02-26
Long OCBC
抱歉,原内容已删除
去老虎APP查看更多动态
{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3576536631283699","uuid":"3576536631283699","gmtCreate":1613445554655,"gmtModify":1613453683209,"name":"VictorChai","pinyin":"victorchai","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/a7c7f08ef3e59c50cc7d2c2579cf1b58","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":3,"headSize":8,"tweetSize":6,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖(非转发)","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":1,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"228c86a078844d74991fff2b7ab2428d-1","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资经理虎","description":"证券账户累计交易金额达到10万美元","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"60.71%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.07.02","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"35ec162348d5460f88c959321e554969-1","templateUuid":"35ec162348d5460f88c959321e554969","name":"精英交易员","description":"证券或期货账户累计交易次数达到30次","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.04.15","exceedPercentage":"60.82%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.01.22","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":187302977,"gmtCreate":1623738279199,"gmtModify":1634029305549,"author":{"id":"3576536631283699","authorId":"3576536631283699","name":"VictorChai","avatar":"https://static.tigerbbs.com/a7c7f08ef3e59c50cc7d2c2579cf1b58","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576536631283699","authorIdStr":"3576536631283699"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a> Long Apple","listText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a> Long Apple","text":"$Apple(AAPL)$ Long Apple","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/187302977","isVote":1,"tweetType":1,"viewCount":92,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":187301531,"gmtCreate":1623738184023,"gmtModify":1634029307677,"author":{"id":"3576536631283699","authorId":"3576536631283699","name":"VictorChai","avatar":"https://static.tigerbbs.com/a7c7f08ef3e59c50cc7d2c2579cf1b58","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576536631283699","authorIdStr":"3576536631283699"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/187301531","repostId":"1177646539","repostType":4,"isVote":1,"tweetType":1,"viewCount":128,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":187303466,"gmtCreate":1623738134155,"gmtModify":1634029308264,"author":{"id":"3576536631283699","authorId":"3576536631283699","name":"VictorChai","avatar":"https://static.tigerbbs.com/a7c7f08ef3e59c50cc7d2c2579cf1b58","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576536631283699","authorIdStr":"3576536631283699"},"themes":[],"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/187303466","repostId":"2143178756","repostType":4,"isVote":1,"tweetType":1,"viewCount":72,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":320058987,"gmtCreate":1614993240849,"gmtModify":1703484011411,"author":{"id":"3576536631283699","authorId":"3576536631283699","name":"VictorChai","avatar":"https://static.tigerbbs.com/a7c7f08ef3e59c50cc7d2c2579cf1b58","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576536631283699","authorIdStr":"3576536631283699"},"themes":[],"htmlText":"Price below $700 would be a good entry point","listText":"Price below $700 would be a good entry point","text":"Price below $700 would be a good entry point","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/320058987","repostId":"2117639609","repostType":4,"repost":{"id":"2117639609","pubTimestamp":1614957600,"share":"https://www.laohu8.com/m/news/2117639609?lang=&edition=full","pubTime":"2021-03-05 23:20","market":"us","language":"en","title":"What's the Outlook for Intuitive Surgical?","url":"https://stock-news.laohu8.com/highlight/detail?id=2117639609","media":"Jason Hawthorne","summary":"Competition is heating up, but the company's market leadership remains unchallenged.","content":"<p>After being relegated to science fiction for most of the 20th century, robots have been more visible over the past two decades. Although most real-world applications so far have been industrial, <b>Intuitive</b> <b>Surgical</b> (NASDAQ:ISRG) has been slowly changing that. The company's da Vinci surgical systems only assist trained humans, but they have become synonymous with the term \"robotic surgery.\"</p><p>After so much success, interested investors will want to determine whether the future can be as bright as the past, or if the combination of COVID, regulatory hurdles, and competition will chip away at the dominance this company has established since going public in 2000.</p><p><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F615724%2Fgettyimages-1218322943.jpg&w=700&op=resize\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p><p>The arms of a surgical robot. Image source: Getty Images.</p><p><b>Managing through COVID-19</b></p><p>Early during the pandemic, when hospitals were stopping elective procedures to dedicate resources to patients with COVID-19, the company's sales tumbled. Year-over-year revenue declined 22% in the second quarter of 2020 on 19% fewer procedures.</p><p>Procedures and revenue rebounded slightly in the following quarter, up 7% and down 4.5%, respectively, compared to 2019. The fourth quarter finally saw year-over-year revenue growth of 4%, but management remained cautious.</p><p>Citing a holiday rise in COVID-19 cases, CEO Gary Guthart pointed to a lag in diagnostic cases at hospitals and weak surgery data spilling over from December into January as an indication that the sales of da Vinci systems would take several quarters to normalize. With fewer cases, utilization of existing machines will remain low, delaying the need to add capacity.</p><p>Although this is definitely a concern, it's a temporary <a href=\"https://laohu8.com/S/AONE\">one</a>. By the end of 2021, orders and installations should be back to normal. System growth has averaged 12% a year over the past decade and 28% for the three years prior to the pandemic. Investors are hoping the return to normal comes sooner rather than later.</p><p><b>A changing regulatory landscape</b></p><p>In recent quarters, management has become much more vocal about a shifting regulatory landscape in the U.S. and Europe, and the requirement for more data than ever before prior to approval. Guthart has said the requirements have stabilized at a level higher than in past years. Although it's a short-term nuisance, this change stands to benefit incumbents like Intuitive over time, because existing systems will sit on the market longer while innovations wait for approval.</p><p>One region where the company has drastically different regulatory experiences is Asia. Guthart has repeatedly cited South Korea as being quick to allow innovative products to market, while China's centrally managed system is more cautious. System sales in the region grew 60% from 2018 to 2019 before falling off during 2020 due to the pandemic. Products launched in China must have a longer history of performance because that country's version of the Food and Drug Administration handles first-generation products very cautiously. Regardless, the company remains excited about its joint venture with Chinese company Fosun Pharma and expects strong, if somewhat turbulent, demand over time.</p><p><b>Defending the moat</b></p><p>One of the risks in China is the launch of companies trying to bring competitive surgical systems to market. This has already happened in South Korea. That country's embrace of innovation is a double-edged sword for Intuitive -- South Korea's first approved surgical robot was made by <b>Meere</b> back in 2017.</p><p>Asia isn't the only region where companies are tired of Intuitive reaping the lion's share of the robotic surgery opportunity. Closer to home, the company faces long-awaited challenges from device makers <b>Medtronic</b> (NYSE:MDT) and <b>Johnson</b> <b>&</b> <b>Johnson</b> (NYSE:JNJ).</p><p>Medtronic made its intentions clear by acquiring spine surgery innovator Mazor Robotics in 2018. It is planning a launch of its Hugo surgical system outside the U.S. to collect data, and expects to submit for an investigational device exemption from the FDA in the next month. That designation would allow the device to be used in a clinical study.</p><p>Johnson & Johnson has a not-so-secret weapon in the battle for the robotic surgery market: the founder of Intuitive Surgical. Dr. Fred Moll, who practically invented the industry when he founded Intuitive in 1995, is chief development officer at the company's devices unit. With his guidance, the healthcare giant plans to commercialize three robotic platforms it gained via acquisition.</p><p>First, the Velys platform is for total knee replacements. This is the type of high-volume, repeatable procedure that is ripe for robotic assistance. But it's a threat to <b>Stryker</b> and <b>Smith</b> <b>&</b> <b>Nephew</b>, not Intuitive.</p><p>Second, the Monarch platform is for a procedure that lets doctors inspect the lungs and air passages. It will eventually be used for lung biopsies, but Intuitive is already staking a claim here with its Ion system. In fact, Intuitive received FDA approval for the procedure in the first quarter of 2019.</p><p>And third, Johnson & Johnson's Ottava general surgery system was introduced in November after much anticipation. The device integrates with an operating table and has six arms, several more than systems currently on the market. The goal is flexibility. If Ottava can perform many types of operations, it will help hospitals avoid buying multiple robots, each with a different purpose. The system is unlikely to come to market before 2024.</p><p><b>Clear skies, with a few clouds on the horizon</b></p><p>Despite some regulatory red tape at home and upstart competition abroad, the path for Intuitive Surgical to continue its decades of growth seems clear. The company is well ahead of the competition with nearly 6,000 surgical systems already installed around the globe, and it will be hard for competitors to replace them. That is especially true as innovation in da Vinci systems, instrumentation, and capability continues to increase both machine utilization and company sales.</p><p>As a shareholder, I'll be watching the regulatory progress of the competing systems. But changes in the approval process have only made it harder for the competition to get a foothold. With no imminent threats for at least the next few years, the shares will stay tucked away in a part of my portfolio as far from the sell button as any I own. For those looking to add the stock to their own portfolios, the recent market volatility may have provided the opportunity they've been waiting for.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>What's the Outlook for Intuitive Surgical?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhat's the Outlook for Intuitive Surgical?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-05 23:20 GMT+8 <a href=https://www.fool.com/investing/2021/03/05/whats-the-outlook-for-intuitive-surgical/><strong>Jason Hawthorne</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After being relegated to science fiction for most of the 20th century, robots have been more visible over the past two decades. Although most real-world applications so far have been industrial, ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/03/05/whats-the-outlook-for-intuitive-surgical/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F615724%2Fgettyimages-1218322943.jpg&w=700&op=resize","relate_stocks":{"ISRG":"直觉外科公司"},"source_url":"https://www.fool.com/investing/2021/03/05/whats-the-outlook-for-intuitive-surgical/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2117639609","content_text":"After being relegated to science fiction for most of the 20th century, robots have been more visible over the past two decades. Although most real-world applications so far have been industrial, Intuitive Surgical (NASDAQ:ISRG) has been slowly changing that. The company's da Vinci surgical systems only assist trained humans, but they have become synonymous with the term \"robotic surgery.\"After so much success, interested investors will want to determine whether the future can be as bright as the past, or if the combination of COVID, regulatory hurdles, and competition will chip away at the dominance this company has established since going public in 2000.The arms of a surgical robot. Image source: Getty Images.Managing through COVID-19Early during the pandemic, when hospitals were stopping elective procedures to dedicate resources to patients with COVID-19, the company's sales tumbled. Year-over-year revenue declined 22% in the second quarter of 2020 on 19% fewer procedures.Procedures and revenue rebounded slightly in the following quarter, up 7% and down 4.5%, respectively, compared to 2019. The fourth quarter finally saw year-over-year revenue growth of 4%, but management remained cautious.Citing a holiday rise in COVID-19 cases, CEO Gary Guthart pointed to a lag in diagnostic cases at hospitals and weak surgery data spilling over from December into January as an indication that the sales of da Vinci systems would take several quarters to normalize. With fewer cases, utilization of existing machines will remain low, delaying the need to add capacity.Although this is definitely a concern, it's a temporary one. By the end of 2021, orders and installations should be back to normal. System growth has averaged 12% a year over the past decade and 28% for the three years prior to the pandemic. Investors are hoping the return to normal comes sooner rather than later.A changing regulatory landscapeIn recent quarters, management has become much more vocal about a shifting regulatory landscape in the U.S. and Europe, and the requirement for more data than ever before prior to approval. Guthart has said the requirements have stabilized at a level higher than in past years. Although it's a short-term nuisance, this change stands to benefit incumbents like Intuitive over time, because existing systems will sit on the market longer while innovations wait for approval.One region where the company has drastically different regulatory experiences is Asia. Guthart has repeatedly cited South Korea as being quick to allow innovative products to market, while China's centrally managed system is more cautious. System sales in the region grew 60% from 2018 to 2019 before falling off during 2020 due to the pandemic. Products launched in China must have a longer history of performance because that country's version of the Food and Drug Administration handles first-generation products very cautiously. Regardless, the company remains excited about its joint venture with Chinese company Fosun Pharma and expects strong, if somewhat turbulent, demand over time.Defending the moatOne of the risks in China is the launch of companies trying to bring competitive surgical systems to market. This has already happened in South Korea. That country's embrace of innovation is a double-edged sword for Intuitive -- South Korea's first approved surgical robot was made by Meere back in 2017.Asia isn't the only region where companies are tired of Intuitive reaping the lion's share of the robotic surgery opportunity. Closer to home, the company faces long-awaited challenges from device makers Medtronic (NYSE:MDT) and Johnson & Johnson (NYSE:JNJ).Medtronic made its intentions clear by acquiring spine surgery innovator Mazor Robotics in 2018. It is planning a launch of its Hugo surgical system outside the U.S. to collect data, and expects to submit for an investigational device exemption from the FDA in the next month. That designation would allow the device to be used in a clinical study.Johnson & Johnson has a not-so-secret weapon in the battle for the robotic surgery market: the founder of Intuitive Surgical. Dr. Fred Moll, who practically invented the industry when he founded Intuitive in 1995, is chief development officer at the company's devices unit. With his guidance, the healthcare giant plans to commercialize three robotic platforms it gained via acquisition.First, the Velys platform is for total knee replacements. This is the type of high-volume, repeatable procedure that is ripe for robotic assistance. But it's a threat to Stryker and Smith & Nephew, not Intuitive.Second, the Monarch platform is for a procedure that lets doctors inspect the lungs and air passages. It will eventually be used for lung biopsies, but Intuitive is already staking a claim here with its Ion system. In fact, Intuitive received FDA approval for the procedure in the first quarter of 2019.And third, Johnson & Johnson's Ottava general surgery system was introduced in November after much anticipation. The device integrates with an operating table and has six arms, several more than systems currently on the market. The goal is flexibility. If Ottava can perform many types of operations, it will help hospitals avoid buying multiple robots, each with a different purpose. The system is unlikely to come to market before 2024.Clear skies, with a few clouds on the horizonDespite some regulatory red tape at home and upstart competition abroad, the path for Intuitive Surgical to continue its decades of growth seems clear. The company is well ahead of the competition with nearly 6,000 surgical systems already installed around the globe, and it will be hard for competitors to replace them. That is especially true as innovation in da Vinci systems, instrumentation, and capability continues to increase both machine utilization and company sales.As a shareholder, I'll be watching the regulatory progress of the competing systems. But changes in the approval process have only made it harder for the competition to get a foothold. With no imminent threats for at least the next few years, the shares will stay tucked away in a part of my portfolio as far from the sell button as any I own. For those looking to add the stock to their own portfolios, the recent market volatility may have provided the opportunity they've been waiting for.","news_type":1},"isVote":1,"tweetType":1,"viewCount":13,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":367124675,"gmtCreate":1614924733697,"gmtModify":1703483031567,"author":{"id":"3576536631283699","authorId":"3576536631283699","name":"VictorChai","avatar":"https://static.tigerbbs.com/a7c7f08ef3e59c50cc7d2c2579cf1b58","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576536631283699","authorIdStr":"3576536631283699"},"themes":[],"htmlText":"Time to shop on Taobao","listText":"Time to shop on Taobao","text":"Time to shop on Taobao","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/367124675","repostId":"2117685330","repostType":4,"isVote":1,"tweetType":1,"viewCount":104,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":368592982,"gmtCreate":1614335532446,"gmtModify":1703476527465,"author":{"id":"3576536631283699","authorId":"3576536631283699","name":"VictorChai","avatar":"https://static.tigerbbs.com/a7c7f08ef3e59c50cc7d2c2579cf1b58","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576536631283699","authorIdStr":"3576536631283699"},"themes":[],"htmlText":"Long OCBC","listText":"Long OCBC","text":"Long OCBC","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/368592982","repostId":"1106176819","repostType":4,"isVote":1,"tweetType":1,"viewCount":282,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":368592982,"gmtCreate":1614335532446,"gmtModify":1703476527465,"author":{"id":"3576536631283699","authorId":"3576536631283699","name":"VictorChai","avatar":"https://static.tigerbbs.com/a7c7f08ef3e59c50cc7d2c2579cf1b58","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3576536631283699","idStr":"3576536631283699"},"themes":[],"htmlText":"Long OCBC","listText":"Long OCBC","text":"Long OCBC","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/368592982","repostId":"1106176819","repostType":4,"isVote":1,"tweetType":1,"viewCount":282,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":367124675,"gmtCreate":1614924733697,"gmtModify":1703483031567,"author":{"id":"3576536631283699","authorId":"3576536631283699","name":"VictorChai","avatar":"https://static.tigerbbs.com/a7c7f08ef3e59c50cc7d2c2579cf1b58","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3576536631283699","idStr":"3576536631283699"},"themes":[],"htmlText":"Time to shop on Taobao","listText":"Time to shop on Taobao","text":"Time to shop on Taobao","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/367124675","repostId":"2117685330","repostType":4,"repost":{"id":"2117685330","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1614918315,"share":"https://www.laohu8.com/m/news/2117685330?lang=&edition=full","pubTime":"2021-03-05 12:25","market":"sh","language":"en","title":"Yuan briefly hits 5-week low, steadies as annual parliament meeting begins","url":"https://stock-news.laohu8.com/highlight/detail?id=2117685330","media":"Reuters","summary":"SHANGHAI, March 5 (Reuters) - The yuan briefly hit an over five-week low against a firmer dollar on ","content":"<p>SHANGHAI, March 5 (Reuters) - The yuan briefly hit an over five-week low against a firmer dollar on Friday before recovering some ground by midday, as investors refrained from testing key ley levels while China's annual meeting of parliament came underway.</p><p>The onshore spot yuan opened at 6.4747 per dollar and slipped to a low of 6.4924 at <a href=\"https://laohu8.com/S/AONE\">one</a> point in morning trade, the softest level since Feb. 26.</p><p>By midday, the yuan was changing hands at 6.4728, 20 pips weaker than the previous late session close, and traders said it was expected to trade sideways at around 6.4730 for the remainder of the session.</p><p>A trader at a foreign bank said the spot market spontaneously stabilised as the annual meeting of parliament started this morning, and investors usually avoided volatility in the financial markets during high-profile political events.</p><p>Separately, some market watchers said they were surprised by the annual economic goals that came in weaker than they had expected.</p><p>China on Friday restored its annual economic growth target, setting it at above 6%, and pledged to create more jobs in cities than last year, as the world's second-biggest economy emerged from a year disrupted by the effects of COVID-19.</p><p>\"There is in fact not much surprise from the government work report except for the super-low GDP target,\" said Iris Pang, chief economist for Greater China at ING.</p><p>\"This makes me feel uneasy as I don't know what exactly the government wants to tell us about the recovery path it expects.\"</p><p>Pang added that other wording on the fiscal and monetary policies remained the same as last year.</p><p>Some analysts said the lower-than-expected growth target could allow the government to deal with other economic problems.</p><p>\"2021 offers a rare opportunity since 2008 in the sense that the government has absolutely no pressure to maintain growth,\" said Zhang Zhiwei, chief economist at Pinpoint Asset Management.</p><p>\"There is no doubt China will achieve it, likely by a large margin,\" he said, adding the government could have capacity to pay more effort dealing with issues including deleveraging.</p><p>Prior to market opening, the People's Bank of China (PBOC) set the midpoint at 6.4904 yuan per dollar, 146 pips, or 0.22%, weaker than the previous fix of 6.4758. It was the weakest since Jan. 4.</p><p>The weaker fixing has pushed China's trade-weighted yuan basket index to 97.06, the highest since June 22, 2018, according to Reuters' calculation based on official data.</p><p>By midday, the global dollar index stood at 91.634, while the offshore yuan was trading at 6.4822 per dollar.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Yuan briefly hits 5-week low, steadies as annual parliament meeting begins</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nYuan briefly hits 5-week low, steadies as annual parliament meeting begins\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-03-05 12:25</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>SHANGHAI, March 5 (Reuters) - The yuan briefly hit an over five-week low against a firmer dollar on Friday before recovering some ground by midday, as investors refrained from testing key ley levels while China's annual meeting of parliament came underway.</p><p>The onshore spot yuan opened at 6.4747 per dollar and slipped to a low of 6.4924 at <a href=\"https://laohu8.com/S/AONE\">one</a> point in morning trade, the softest level since Feb. 26.</p><p>By midday, the yuan was changing hands at 6.4728, 20 pips weaker than the previous late session close, and traders said it was expected to trade sideways at around 6.4730 for the remainder of the session.</p><p>A trader at a foreign bank said the spot market spontaneously stabilised as the annual meeting of parliament started this morning, and investors usually avoided volatility in the financial markets during high-profile political events.</p><p>Separately, some market watchers said they were surprised by the annual economic goals that came in weaker than they had expected.</p><p>China on Friday restored its annual economic growth target, setting it at above 6%, and pledged to create more jobs in cities than last year, as the world's second-biggest economy emerged from a year disrupted by the effects of COVID-19.</p><p>\"There is in fact not much surprise from the government work report except for the super-low GDP target,\" said Iris Pang, chief economist for Greater China at ING.</p><p>\"This makes me feel uneasy as I don't know what exactly the government wants to tell us about the recovery path it expects.\"</p><p>Pang added that other wording on the fiscal and monetary policies remained the same as last year.</p><p>Some analysts said the lower-than-expected growth target could allow the government to deal with other economic problems.</p><p>\"2021 offers a rare opportunity since 2008 in the sense that the government has absolutely no pressure to maintain growth,\" said Zhang Zhiwei, chief economist at Pinpoint Asset Management.</p><p>\"There is no doubt China will achieve it, likely by a large margin,\" he said, adding the government could have capacity to pay more effort dealing with issues including deleveraging.</p><p>Prior to market opening, the People's Bank of China (PBOC) set the midpoint at 6.4904 yuan per dollar, 146 pips, or 0.22%, weaker than the previous fix of 6.4758. It was the weakest since Jan. 4.</p><p>The weaker fixing has pushed China's trade-weighted yuan basket index to 97.06, the highest since June 22, 2018, according to Reuters' calculation based on official data.</p><p>By midday, the global dollar index stood at 91.634, while the offshore yuan was trading at 6.4822 per dollar.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CYB":"人民币ETF-WisdomTree Dreyfus"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2117685330","content_text":"SHANGHAI, March 5 (Reuters) - The yuan briefly hit an over five-week low against a firmer dollar on Friday before recovering some ground by midday, as investors refrained from testing key ley levels while China's annual meeting of parliament came underway.The onshore spot yuan opened at 6.4747 per dollar and slipped to a low of 6.4924 at one point in morning trade, the softest level since Feb. 26.By midday, the yuan was changing hands at 6.4728, 20 pips weaker than the previous late session close, and traders said it was expected to trade sideways at around 6.4730 for the remainder of the session.A trader at a foreign bank said the spot market spontaneously stabilised as the annual meeting of parliament started this morning, and investors usually avoided volatility in the financial markets during high-profile political events.Separately, some market watchers said they were surprised by the annual economic goals that came in weaker than they had expected.China on Friday restored its annual economic growth target, setting it at above 6%, and pledged to create more jobs in cities than last year, as the world's second-biggest economy emerged from a year disrupted by the effects of COVID-19.\"There is in fact not much surprise from the government work report except for the super-low GDP target,\" said Iris Pang, chief economist for Greater China at ING.\"This makes me feel uneasy as I don't know what exactly the government wants to tell us about the recovery path it expects.\"Pang added that other wording on the fiscal and monetary policies remained the same as last year.Some analysts said the lower-than-expected growth target could allow the government to deal with other economic problems.\"2021 offers a rare opportunity since 2008 in the sense that the government has absolutely no pressure to maintain growth,\" said Zhang Zhiwei, chief economist at Pinpoint Asset Management.\"There is no doubt China will achieve it, likely by a large margin,\" he said, adding the government could have capacity to pay more effort dealing with issues including deleveraging.Prior to market opening, the People's Bank of China (PBOC) set the midpoint at 6.4904 yuan per dollar, 146 pips, or 0.22%, weaker than the previous fix of 6.4758. It was the weakest since Jan. 4.The weaker fixing has pushed China's trade-weighted yuan basket index to 97.06, the highest since June 22, 2018, according to Reuters' calculation based on official data.By midday, the global dollar index stood at 91.634, while the offshore yuan was trading at 6.4822 per dollar.","news_type":1},"isVote":1,"tweetType":1,"viewCount":104,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":187301531,"gmtCreate":1623738184023,"gmtModify":1634029307677,"author":{"id":"3576536631283699","authorId":"3576536631283699","name":"VictorChai","avatar":"https://static.tigerbbs.com/a7c7f08ef3e59c50cc7d2c2579cf1b58","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3576536631283699","idStr":"3576536631283699"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/187301531","repostId":"1177646539","repostType":4,"repost":{"id":"1177646539","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1623737223,"share":"https://www.laohu8.com/m/news/1177646539?lang=&edition=full","pubTime":"2021-06-15 14:07","market":"us","language":"en","title":"3 Commodity Stocks To Consider For Inflation","url":"https://stock-news.laohu8.com/highlight/detail?id=1177646539","media":"Benzinga","summary":"As inflation heats up, the stocks of some commodity-based companies can move higher. These companies","content":"<p>As inflation heats up, the stocks of some commodity-based companies can move higher. These companies hold a large part of their assets in commodities, so as their prices move higher, the companies become more valuable.</p>\n<p>They include <b>Exxon Mobil Corporation</b>(NYSE:XOM),<b>Southern Copper Corporation</b>(NYSE:SCCO), and <b>Newmont Corporation</b>(NYSE:NEM).</p>\n<p>Exxon benefits from higher oil prices. The stock has hit resistance at the $63.50 level and it could be on the verge of a breakout.</p>\n<p><img src=\"https://static.tigerbbs.com/db45eed41059ff0878aac7b6b4e2fee7\" tg-width=\"1618\" tg-height=\"823\"></p>\n<p>Southern Copper benefits from higher copper prices. Shares have dropped to support around the $67 level and there’s a chance they rebound.</p>\n<p><img src=\"https://static.tigerbbs.com/543514dbd50dbb41ce5748225d9e606d\" tg-width=\"1615\" tg-height=\"814\"></p>\n<p>Newmont is a gold miner. As the price of gold increases, so does its value. The shares are close to the $68.50 level and there’s a chance they find support and rally.</p>\n<p><img src=\"https://static.tigerbbs.com/f699df6d7097a731136d18e4e57324e2\" tg-width=\"1619\" tg-height=\"817\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Commodity Stocks To Consider For Inflation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Commodity Stocks To Consider For Inflation\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-06-15 14:07</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>As inflation heats up, the stocks of some commodity-based companies can move higher. These companies hold a large part of their assets in commodities, so as their prices move higher, the companies become more valuable.</p>\n<p>They include <b>Exxon Mobil Corporation</b>(NYSE:XOM),<b>Southern Copper Corporation</b>(NYSE:SCCO), and <b>Newmont Corporation</b>(NYSE:NEM).</p>\n<p>Exxon benefits from higher oil prices. The stock has hit resistance at the $63.50 level and it could be on the verge of a breakout.</p>\n<p><img src=\"https://static.tigerbbs.com/db45eed41059ff0878aac7b6b4e2fee7\" tg-width=\"1618\" tg-height=\"823\"></p>\n<p>Southern Copper benefits from higher copper prices. Shares have dropped to support around the $67 level and there’s a chance they rebound.</p>\n<p><img src=\"https://static.tigerbbs.com/543514dbd50dbb41ce5748225d9e606d\" tg-width=\"1615\" tg-height=\"814\"></p>\n<p>Newmont is a gold miner. As the price of gold increases, so does its value. The shares are close to the $68.50 level and there’s a chance they find support and rally.</p>\n<p><img src=\"https://static.tigerbbs.com/f699df6d7097a731136d18e4e57324e2\" tg-width=\"1619\" tg-height=\"817\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"XOM":"埃克森美孚","NEM":"纽曼矿业","SCCO":"南方铜业"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1177646539","content_text":"As inflation heats up, the stocks of some commodity-based companies can move higher. These companies hold a large part of their assets in commodities, so as their prices move higher, the companies become more valuable.\nThey include Exxon Mobil Corporation(NYSE:XOM),Southern Copper Corporation(NYSE:SCCO), and Newmont Corporation(NYSE:NEM).\nExxon benefits from higher oil prices. The stock has hit resistance at the $63.50 level and it could be on the verge of a breakout.\n\nSouthern Copper benefits from higher copper prices. Shares have dropped to support around the $67 level and there’s a chance they rebound.\n\nNewmont is a gold miner. As the price of gold increases, so does its value. The shares are close to the $68.50 level and there’s a chance they find support and rally.","news_type":1},"isVote":1,"tweetType":1,"viewCount":128,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":187303466,"gmtCreate":1623738134155,"gmtModify":1634029308264,"author":{"id":"3576536631283699","authorId":"3576536631283699","name":"VictorChai","avatar":"https://static.tigerbbs.com/a7c7f08ef3e59c50cc7d2c2579cf1b58","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3576536631283699","idStr":"3576536631283699"},"themes":[],"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/187303466","repostId":"2143178756","repostType":4,"repost":{"id":"2143178756","pubTimestamp":1623719401,"share":"https://www.laohu8.com/m/news/2143178756?lang=&edition=full","pubTime":"2021-06-15 09:10","market":"us","language":"en","title":"3 Stocks to Avoid This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2143178756","media":"Motley Fool","summary":"These investments seem pretty vulnerable right now.","content":"<p>In last week's article on three stocks to avoid, I predicted that <b>GameStop</b> (NYSE:GME), <b>AMC Entertainment Holdings</b> (NYSE:AMC), and <b>Carnival</b> (NYSE:CCL) would have a rough few days.</p>\n<ul>\n <li>GameStop lived up to my prediction on tumbling the day after reporting quarterly results, something that has now happened in 10 of the past 11 reports. The video game retailer plummeted 27% on Thursday, but it moved nicely higher the other four days of the week -- trimming its weeklong decline to just 6%.</li>\n <li>AMC closed out the week with a 3% gain, following the 83% burst higher the week before. The multiplex operator is benefiting from a surge in box office receipts, but they continue to track at less than half of where the industry was two years ago.</li>\n <li>Finally we have Carnival sinking 2% for the week. Cruise stocks have been buoyant ahead of a return to sailing this month, but we're already seeing COVID-19 cases pop up in the limited number of voyages taking place so far.</li>\n</ul>\n<p>Those three stocks averaged a 1.7% decline for the week. The <b>S&P 500</b> rose by 0.4% in that time, so I won. Right now, I see <b>Royal Caribbean</b> (NYSE:RCL), AMC Entertainment Holdings, and <b>Osprey Bitcoin Trust</b> (OTC:OBTC) as vulnerable investments in the near term. Here's why I think these are three stocks to avoid this week.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/844fa22418b0d6398103c6917b0d7eb3\" tg-width=\"700\" tg-height=\"459\"><span>Image source: Getty Images.</span></p>\n<h2>1. Royal Caribbean</h2>\n<p>This was supposed to be the summer that the cruise industry finally roars back into being, but we're already seeing some choppy waters. Royal Caribbean's <i>Celebrity Millennium</i> became the first major cruise ship available to North American seafarers earlier this month since the industry shut down last March. A few days into the maiden voyage, a pair of passengers contracted the COVID-19 virus.</p>\n<p>There's also an operational standoff in Royal Caribbean's home state of Florida, where the governor is threatening to fine cruise lines for requiring vaccinations of its passengers. It's a Catch-22 for the industry, as the CDC requires at least 95% of a ship's passengers to be fully vaccinated to resume sailings without having to go through a series of costly test cruises.</p>\n<p>Royal Caribbean is my favorite of the three cruise lines as an investment, but it's also held up the best during the lull. With the reopening off to a bumpy start it also makes the stock vulnerable here.</p>\n<h2><b>2. AMC Entertainment</b></h2>\n<p>I'm a fan of a lot that AMC Entertainment has done to get bet better at a time when many of its smaller rivals have been merely walking in place. The country's largest multiplex operator has upped its seat reservations and mobile order tech and carved out a new revenue stream with actively promoted private rentals. The new Investor Connect program is sheer genius, monetizing its newborn attention as a meme stock with millions of retail investors by trying to convert them into customers.</p>\n<p>However, after ballooning its share count north of 500 million -- and the stock still moving higher -- there will eventually be a price to be paid in terms of valuation. AMC Entertainment enters this week with an enterprise value above $35 billion, and sooner or later someone is going to have to pay the tab at the end of the party.</p>\n<p>AMC is doing the right things to stay on top of a declining industry, but it's not enough to justify today's sticker price. This has historically been a low-margin business -- in the low single digits for net margin most years -- despite the markup on concessions. You'll see a year-over-year bounce this year, but we may never return to 2019 as a baseline. Theatrical release windows are being shattered by streaming initiatives. AMC has bloated its debt levels and share count to stay alive, but all of this comes at a price that right now seems too dear to pay.</p>\n<h2>3. Osprey Bitcoin Trust</h2>\n<p>I believe in keeping a small percent of your risk-tolerant portfolio in crypto, but not every vehicle is in the same boat. Osprey Bitcoin Trust offers investors a low-cost way to play the popularity of <b>Bitcoin</b> (CRYPTO:BTC) in a stock exchange-listed vehicle.</p>\n<p>Osprey Bitcoin Trust is a lot smaller than the market's original Bitcoin-owning trust, and it's also trading at an unsustainable premium. Osprey's mark-up to its stake of Bitcoin tokens has been contracting since hitting the market earlier this year, and I was starting to get interested when the premium narrowed to 12% a week ago.</p>\n<p>The mark-up is going the wrong way again. Osprey Bitcoin Trust owns what is currently $12.68 in Bitcoin, but it closed last week at $14.95. Is an 18% premium worth it when the much larger -- but admittedly more high-cost -- <b>Grayscale Bitcoin Trust</b> (OTC:GBTC) is fetching an 11% discount to its net asset value?</p>\n<p>If you're looking for safe stocks, you aren't likely to find them in Royal Caribbean, AMC Entertainment, and Osprey Bitcoin Trust this week.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks to Avoid This Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks to Avoid This Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-15 09:10 GMT+8 <a href=https://www.fool.com/investing/2021/06/14/3-stocks-to-avoid-this-week/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In last week's article on three stocks to avoid, I predicted that GameStop (NYSE:GME), AMC Entertainment Holdings (NYSE:AMC), and Carnival (NYSE:CCL) would have a rough few days.\n\nGameStop lived up to...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/14/3-stocks-to-avoid-this-week/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CCL":"嘉年华邮轮","OBTC":"Osprey Bitcoin Trust","AMC":"AMC院线","GME":"游戏驿站"},"source_url":"https://www.fool.com/investing/2021/06/14/3-stocks-to-avoid-this-week/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2143178756","content_text":"In last week's article on three stocks to avoid, I predicted that GameStop (NYSE:GME), AMC Entertainment Holdings (NYSE:AMC), and Carnival (NYSE:CCL) would have a rough few days.\n\nGameStop lived up to my prediction on tumbling the day after reporting quarterly results, something that has now happened in 10 of the past 11 reports. The video game retailer plummeted 27% on Thursday, but it moved nicely higher the other four days of the week -- trimming its weeklong decline to just 6%.\nAMC closed out the week with a 3% gain, following the 83% burst higher the week before. The multiplex operator is benefiting from a surge in box office receipts, but they continue to track at less than half of where the industry was two years ago.\nFinally we have Carnival sinking 2% for the week. Cruise stocks have been buoyant ahead of a return to sailing this month, but we're already seeing COVID-19 cases pop up in the limited number of voyages taking place so far.\n\nThose three stocks averaged a 1.7% decline for the week. The S&P 500 rose by 0.4% in that time, so I won. Right now, I see Royal Caribbean (NYSE:RCL), AMC Entertainment Holdings, and Osprey Bitcoin Trust (OTC:OBTC) as vulnerable investments in the near term. Here's why I think these are three stocks to avoid this week.\nImage source: Getty Images.\n1. Royal Caribbean\nThis was supposed to be the summer that the cruise industry finally roars back into being, but we're already seeing some choppy waters. Royal Caribbean's Celebrity Millennium became the first major cruise ship available to North American seafarers earlier this month since the industry shut down last March. A few days into the maiden voyage, a pair of passengers contracted the COVID-19 virus.\nThere's also an operational standoff in Royal Caribbean's home state of Florida, where the governor is threatening to fine cruise lines for requiring vaccinations of its passengers. It's a Catch-22 for the industry, as the CDC requires at least 95% of a ship's passengers to be fully vaccinated to resume sailings without having to go through a series of costly test cruises.\nRoyal Caribbean is my favorite of the three cruise lines as an investment, but it's also held up the best during the lull. With the reopening off to a bumpy start it also makes the stock vulnerable here.\n2. AMC Entertainment\nI'm a fan of a lot that AMC Entertainment has done to get bet better at a time when many of its smaller rivals have been merely walking in place. The country's largest multiplex operator has upped its seat reservations and mobile order tech and carved out a new revenue stream with actively promoted private rentals. The new Investor Connect program is sheer genius, monetizing its newborn attention as a meme stock with millions of retail investors by trying to convert them into customers.\nHowever, after ballooning its share count north of 500 million -- and the stock still moving higher -- there will eventually be a price to be paid in terms of valuation. AMC Entertainment enters this week with an enterprise value above $35 billion, and sooner or later someone is going to have to pay the tab at the end of the party.\nAMC is doing the right things to stay on top of a declining industry, but it's not enough to justify today's sticker price. This has historically been a low-margin business -- in the low single digits for net margin most years -- despite the markup on concessions. You'll see a year-over-year bounce this year, but we may never return to 2019 as a baseline. Theatrical release windows are being shattered by streaming initiatives. AMC has bloated its debt levels and share count to stay alive, but all of this comes at a price that right now seems too dear to pay.\n3. Osprey Bitcoin Trust\nI believe in keeping a small percent of your risk-tolerant portfolio in crypto, but not every vehicle is in the same boat. Osprey Bitcoin Trust offers investors a low-cost way to play the popularity of Bitcoin (CRYPTO:BTC) in a stock exchange-listed vehicle.\nOsprey Bitcoin Trust is a lot smaller than the market's original Bitcoin-owning trust, and it's also trading at an unsustainable premium. Osprey's mark-up to its stake of Bitcoin tokens has been contracting since hitting the market earlier this year, and I was starting to get interested when the premium narrowed to 12% a week ago.\nThe mark-up is going the wrong way again. Osprey Bitcoin Trust owns what is currently $12.68 in Bitcoin, but it closed last week at $14.95. Is an 18% premium worth it when the much larger -- but admittedly more high-cost -- Grayscale Bitcoin Trust (OTC:GBTC) is fetching an 11% discount to its net asset value?\nIf you're looking for safe stocks, you aren't likely to find them in Royal Caribbean, AMC Entertainment, and Osprey Bitcoin Trust this week.","news_type":1},"isVote":1,"tweetType":1,"viewCount":72,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":320058987,"gmtCreate":1614993240849,"gmtModify":1703484011411,"author":{"id":"3576536631283699","authorId":"3576536631283699","name":"VictorChai","avatar":"https://static.tigerbbs.com/a7c7f08ef3e59c50cc7d2c2579cf1b58","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3576536631283699","idStr":"3576536631283699"},"themes":[],"htmlText":"Price below $700 would be a good entry point","listText":"Price below $700 would be a good entry point","text":"Price below $700 would be a good entry point","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/320058987","repostId":"2117639609","repostType":4,"repost":{"id":"2117639609","pubTimestamp":1614957600,"share":"https://www.laohu8.com/m/news/2117639609?lang=&edition=full","pubTime":"2021-03-05 23:20","market":"us","language":"en","title":"What's the Outlook for Intuitive Surgical?","url":"https://stock-news.laohu8.com/highlight/detail?id=2117639609","media":"Jason Hawthorne","summary":"Competition is heating up, but the company's market leadership remains unchallenged.","content":"<p>After being relegated to science fiction for most of the 20th century, robots have been more visible over the past two decades. Although most real-world applications so far have been industrial, <b>Intuitive</b> <b>Surgical</b> (NASDAQ:ISRG) has been slowly changing that. The company's da Vinci surgical systems only assist trained humans, but they have become synonymous with the term \"robotic surgery.\"</p><p>After so much success, interested investors will want to determine whether the future can be as bright as the past, or if the combination of COVID, regulatory hurdles, and competition will chip away at the dominance this company has established since going public in 2000.</p><p><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F615724%2Fgettyimages-1218322943.jpg&w=700&op=resize\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p><p>The arms of a surgical robot. Image source: Getty Images.</p><p><b>Managing through COVID-19</b></p><p>Early during the pandemic, when hospitals were stopping elective procedures to dedicate resources to patients with COVID-19, the company's sales tumbled. Year-over-year revenue declined 22% in the second quarter of 2020 on 19% fewer procedures.</p><p>Procedures and revenue rebounded slightly in the following quarter, up 7% and down 4.5%, respectively, compared to 2019. The fourth quarter finally saw year-over-year revenue growth of 4%, but management remained cautious.</p><p>Citing a holiday rise in COVID-19 cases, CEO Gary Guthart pointed to a lag in diagnostic cases at hospitals and weak surgery data spilling over from December into January as an indication that the sales of da Vinci systems would take several quarters to normalize. With fewer cases, utilization of existing machines will remain low, delaying the need to add capacity.</p><p>Although this is definitely a concern, it's a temporary <a href=\"https://laohu8.com/S/AONE\">one</a>. By the end of 2021, orders and installations should be back to normal. System growth has averaged 12% a year over the past decade and 28% for the three years prior to the pandemic. Investors are hoping the return to normal comes sooner rather than later.</p><p><b>A changing regulatory landscape</b></p><p>In recent quarters, management has become much more vocal about a shifting regulatory landscape in the U.S. and Europe, and the requirement for more data than ever before prior to approval. Guthart has said the requirements have stabilized at a level higher than in past years. Although it's a short-term nuisance, this change stands to benefit incumbents like Intuitive over time, because existing systems will sit on the market longer while innovations wait for approval.</p><p>One region where the company has drastically different regulatory experiences is Asia. Guthart has repeatedly cited South Korea as being quick to allow innovative products to market, while China's centrally managed system is more cautious. System sales in the region grew 60% from 2018 to 2019 before falling off during 2020 due to the pandemic. Products launched in China must have a longer history of performance because that country's version of the Food and Drug Administration handles first-generation products very cautiously. Regardless, the company remains excited about its joint venture with Chinese company Fosun Pharma and expects strong, if somewhat turbulent, demand over time.</p><p><b>Defending the moat</b></p><p>One of the risks in China is the launch of companies trying to bring competitive surgical systems to market. This has already happened in South Korea. That country's embrace of innovation is a double-edged sword for Intuitive -- South Korea's first approved surgical robot was made by <b>Meere</b> back in 2017.</p><p>Asia isn't the only region where companies are tired of Intuitive reaping the lion's share of the robotic surgery opportunity. Closer to home, the company faces long-awaited challenges from device makers <b>Medtronic</b> (NYSE:MDT) and <b>Johnson</b> <b>&</b> <b>Johnson</b> (NYSE:JNJ).</p><p>Medtronic made its intentions clear by acquiring spine surgery innovator Mazor Robotics in 2018. It is planning a launch of its Hugo surgical system outside the U.S. to collect data, and expects to submit for an investigational device exemption from the FDA in the next month. That designation would allow the device to be used in a clinical study.</p><p>Johnson & Johnson has a not-so-secret weapon in the battle for the robotic surgery market: the founder of Intuitive Surgical. Dr. Fred Moll, who practically invented the industry when he founded Intuitive in 1995, is chief development officer at the company's devices unit. With his guidance, the healthcare giant plans to commercialize three robotic platforms it gained via acquisition.</p><p>First, the Velys platform is for total knee replacements. This is the type of high-volume, repeatable procedure that is ripe for robotic assistance. But it's a threat to <b>Stryker</b> and <b>Smith</b> <b>&</b> <b>Nephew</b>, not Intuitive.</p><p>Second, the Monarch platform is for a procedure that lets doctors inspect the lungs and air passages. It will eventually be used for lung biopsies, but Intuitive is already staking a claim here with its Ion system. In fact, Intuitive received FDA approval for the procedure in the first quarter of 2019.</p><p>And third, Johnson & Johnson's Ottava general surgery system was introduced in November after much anticipation. The device integrates with an operating table and has six arms, several more than systems currently on the market. The goal is flexibility. If Ottava can perform many types of operations, it will help hospitals avoid buying multiple robots, each with a different purpose. The system is unlikely to come to market before 2024.</p><p><b>Clear skies, with a few clouds on the horizon</b></p><p>Despite some regulatory red tape at home and upstart competition abroad, the path for Intuitive Surgical to continue its decades of growth seems clear. The company is well ahead of the competition with nearly 6,000 surgical systems already installed around the globe, and it will be hard for competitors to replace them. That is especially true as innovation in da Vinci systems, instrumentation, and capability continues to increase both machine utilization and company sales.</p><p>As a shareholder, I'll be watching the regulatory progress of the competing systems. But changes in the approval process have only made it harder for the competition to get a foothold. With no imminent threats for at least the next few years, the shares will stay tucked away in a part of my portfolio as far from the sell button as any I own. For those looking to add the stock to their own portfolios, the recent market volatility may have provided the opportunity they've been waiting for.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>What's the Outlook for Intuitive Surgical?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhat's the Outlook for Intuitive Surgical?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-05 23:20 GMT+8 <a href=https://www.fool.com/investing/2021/03/05/whats-the-outlook-for-intuitive-surgical/><strong>Jason Hawthorne</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After being relegated to science fiction for most of the 20th century, robots have been more visible over the past two decades. Although most real-world applications so far have been industrial, ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/03/05/whats-the-outlook-for-intuitive-surgical/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F615724%2Fgettyimages-1218322943.jpg&w=700&op=resize","relate_stocks":{"ISRG":"直觉外科公司"},"source_url":"https://www.fool.com/investing/2021/03/05/whats-the-outlook-for-intuitive-surgical/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2117639609","content_text":"After being relegated to science fiction for most of the 20th century, robots have been more visible over the past two decades. Although most real-world applications so far have been industrial, Intuitive Surgical (NASDAQ:ISRG) has been slowly changing that. The company's da Vinci surgical systems only assist trained humans, but they have become synonymous with the term \"robotic surgery.\"After so much success, interested investors will want to determine whether the future can be as bright as the past, or if the combination of COVID, regulatory hurdles, and competition will chip away at the dominance this company has established since going public in 2000.The arms of a surgical robot. Image source: Getty Images.Managing through COVID-19Early during the pandemic, when hospitals were stopping elective procedures to dedicate resources to patients with COVID-19, the company's sales tumbled. Year-over-year revenue declined 22% in the second quarter of 2020 on 19% fewer procedures.Procedures and revenue rebounded slightly in the following quarter, up 7% and down 4.5%, respectively, compared to 2019. The fourth quarter finally saw year-over-year revenue growth of 4%, but management remained cautious.Citing a holiday rise in COVID-19 cases, CEO Gary Guthart pointed to a lag in diagnostic cases at hospitals and weak surgery data spilling over from December into January as an indication that the sales of da Vinci systems would take several quarters to normalize. With fewer cases, utilization of existing machines will remain low, delaying the need to add capacity.Although this is definitely a concern, it's a temporary one. By the end of 2021, orders and installations should be back to normal. System growth has averaged 12% a year over the past decade and 28% for the three years prior to the pandemic. Investors are hoping the return to normal comes sooner rather than later.A changing regulatory landscapeIn recent quarters, management has become much more vocal about a shifting regulatory landscape in the U.S. and Europe, and the requirement for more data than ever before prior to approval. Guthart has said the requirements have stabilized at a level higher than in past years. Although it's a short-term nuisance, this change stands to benefit incumbents like Intuitive over time, because existing systems will sit on the market longer while innovations wait for approval.One region where the company has drastically different regulatory experiences is Asia. Guthart has repeatedly cited South Korea as being quick to allow innovative products to market, while China's centrally managed system is more cautious. System sales in the region grew 60% from 2018 to 2019 before falling off during 2020 due to the pandemic. Products launched in China must have a longer history of performance because that country's version of the Food and Drug Administration handles first-generation products very cautiously. Regardless, the company remains excited about its joint venture with Chinese company Fosun Pharma and expects strong, if somewhat turbulent, demand over time.Defending the moatOne of the risks in China is the launch of companies trying to bring competitive surgical systems to market. This has already happened in South Korea. That country's embrace of innovation is a double-edged sword for Intuitive -- South Korea's first approved surgical robot was made by Meere back in 2017.Asia isn't the only region where companies are tired of Intuitive reaping the lion's share of the robotic surgery opportunity. Closer to home, the company faces long-awaited challenges from device makers Medtronic (NYSE:MDT) and Johnson & Johnson (NYSE:JNJ).Medtronic made its intentions clear by acquiring spine surgery innovator Mazor Robotics in 2018. It is planning a launch of its Hugo surgical system outside the U.S. to collect data, and expects to submit for an investigational device exemption from the FDA in the next month. That designation would allow the device to be used in a clinical study.Johnson & Johnson has a not-so-secret weapon in the battle for the robotic surgery market: the founder of Intuitive Surgical. Dr. Fred Moll, who practically invented the industry when he founded Intuitive in 1995, is chief development officer at the company's devices unit. With his guidance, the healthcare giant plans to commercialize three robotic platforms it gained via acquisition.First, the Velys platform is for total knee replacements. This is the type of high-volume, repeatable procedure that is ripe for robotic assistance. But it's a threat to Stryker and Smith & Nephew, not Intuitive.Second, the Monarch platform is for a procedure that lets doctors inspect the lungs and air passages. It will eventually be used for lung biopsies, but Intuitive is already staking a claim here with its Ion system. In fact, Intuitive received FDA approval for the procedure in the first quarter of 2019.And third, Johnson & Johnson's Ottava general surgery system was introduced in November after much anticipation. The device integrates with an operating table and has six arms, several more than systems currently on the market. The goal is flexibility. If Ottava can perform many types of operations, it will help hospitals avoid buying multiple robots, each with a different purpose. The system is unlikely to come to market before 2024.Clear skies, with a few clouds on the horizonDespite some regulatory red tape at home and upstart competition abroad, the path for Intuitive Surgical to continue its decades of growth seems clear. The company is well ahead of the competition with nearly 6,000 surgical systems already installed around the globe, and it will be hard for competitors to replace them. That is especially true as innovation in da Vinci systems, instrumentation, and capability continues to increase both machine utilization and company sales.As a shareholder, I'll be watching the regulatory progress of the competing systems. But changes in the approval process have only made it harder for the competition to get a foothold. With no imminent threats for at least the next few years, the shares will stay tucked away in a part of my portfolio as far from the sell button as any I own. For those looking to add the stock to their own portfolios, the recent market volatility may have provided the opportunity they've been waiting for.","news_type":1},"isVote":1,"tweetType":1,"viewCount":13,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":187302977,"gmtCreate":1623738279199,"gmtModify":1634029305549,"author":{"id":"3576536631283699","authorId":"3576536631283699","name":"VictorChai","avatar":"https://static.tigerbbs.com/a7c7f08ef3e59c50cc7d2c2579cf1b58","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3576536631283699","idStr":"3576536631283699"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a> Long Apple","listText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a> Long Apple","text":"$Apple(AAPL)$ Long Apple","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/187302977","isVote":1,"tweetType":1,"viewCount":92,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}